mFOLFOXIRI
Phase 3Small molecule
mFOLFOXIRI is one of 108 small molecule programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.
3
Indications
9
Total Trials
4
Active Trials
107
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
949 competitors in Colorectal Cancer
#DrugCompanyPhaseTrials
1mFOLFOXIRI
DDominik Paul Modest
Phase 3
Eylea
RegeneronPreclinical
Emend IV
Merck & Co.Preclinical
PORTRAZZA
Eli LillyPreclinical
Vascepa
AAmarin Pharma Inc.
Preclinical
Gas-X
PPortuguese Oncology Institute, Coimbra
Preclinical
Ketalar
AAultman Health Foundation
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Versed
CConrado Roberto Hoffmann Filho
Preclinical
Ultiva
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Colorectal Cancer3 trials
mFOLFOXIRI Compared to mFOLFOX6 or CapeOx as Adjuvant Chemotherapy for Stage IIIB or IIIC Colorectal Cancer
Unknown status·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT05200299·100 enrolled
Metastatic Colorectal Cancer2 trials
Locally-advanced Rectal Cancer1 trial
1 more indication
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mFOLFOXIRI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- DDominik Paul Modest